The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area. Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]
As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.
To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.
Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.
The induced pluripotent stem cell (iPSC) market first emerged in 2006, when iPSC technology was pioneered by Shinya Yamanaka’s lab at Kyoto University in Japan. The shocking discovery that the introduction of four transcription factors into adult cells could convert them into pluripotent stem cells sent waves of excitement throughout the scientific community.
This landmark event came to represent one of the greatest stem cell research discoveries of all time and was memorialized in 2012, when Dr. Yamanaka and Sir John Gurdon were awarded the Nobel Prize “for the discovery that mature cells can be reprogrammed to become pluripotent.”
iPSC technology has since revolutionized how stem cells are derived, differentiated, and acquired in industrial quantities. It has also dramatically affected our understanding of how human cells and organisms develop.